126 related articles for article (PubMed ID: 34678477)
21. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
22. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
23. Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis.
Chiofalo B; Bruni S; Certelli C; Sperduti I; Baiocco E; Vizza E
Minerva Med; 2019 Aug; 110(4):330-340. PubMed ID: 31081304
[TBL] [Abstract][Full Text] [Related]
24. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
[TBL] [Abstract][Full Text] [Related]
25. Interval debulking surgery for advanced epithelial ovarian cancer.
Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P; Bryant A
Cochrane Database Syst Rev; 2010 Oct; (10):CD006014. PubMed ID: 20927744
[TBL] [Abstract][Full Text] [Related]
26. The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study.
Bogani G; Matteucci L; Tamberi S; Arcangeli V; Ditto A; Maltese G; Signorelli M; Martinelli F; Chiappa V; Leone Roberti Maggiore U; Perotto S; Scaffa C; Comerci G; Stefanetti M; Raspagliesi F; Lorusso D
Int J Gynecol Cancer; 2017 Nov; 27(9):1856-1862. PubMed ID: 29064913
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.
Liu YL; Filippova OT; Zhou Q; Iasonos A; Chi DS; Zivanovic O; Sonoda Y; Gardner GJ; Broach VA; O'Cearbhaill RE; Konner JA; Aghajanian C; Long Roche K; Tew WP
J Gynecol Oncol; 2020 Jan; 31(1):e17. PubMed ID: 31833259
[TBL] [Abstract][Full Text] [Related]
28. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
[TBL] [Abstract][Full Text] [Related]
29. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
30. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
[TBL] [Abstract][Full Text] [Related]
31. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
32. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
[TBL] [Abstract][Full Text] [Related]
33. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
34. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
Psomiadou V; Prodromidou A; Fotiou A; Lekka S; Iavazzo C
J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
Song N; Gao Y
Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
[TBL] [Abstract][Full Text] [Related]
36. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
Nicklin JL; McGrath S; Tripcony L; Garrett A; Land R; Tang A; Perrin L; Chetty N; Jagasia N; Crandon AJ; Nascimento M; Walker G; Sanday K; Obermair A
Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):651-658. PubMed ID: 28718942
[TBL] [Abstract][Full Text] [Related]
37. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
[TBL] [Abstract][Full Text] [Related]
38. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.
Wang D; Zhang G; Peng C; Shi Y; Shi X
J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
